Last 3,088 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 7:06 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi india ltd (SANL) Snapshot

Open
2,948
Previous Close
2,926
Day High
3,199
Day Low
2,911
52 Week High
04/23/14 - 3,199
52 Week Low
10/28/13 - 2,242
Market Cap
71.1B
Average Volume 10 Days
5.6K
EPS TTM
63.00
Shares Outstanding
23.0M
EX-Date
04/16/14
P/E TM
49.0x
Dividend
45.00
Dividend Yield
1.46%
Current Stock Chart for SANOFI INDIA LTD (SANL)

Related News

No related news articles were found.

sanofi india ltd (SANL) Related Businessweek News

No Related Businessweek News Found

sanofi india ltd (SANL) Details

Sanofi India Limited engages in the manufacture and sale of pharmaceutical products in India. The company provides medicines for the treatment of patients in various therapeutic areas, including cardiology, thrombosis, dermatology, oncology, diabetes, central nervous system, respiratory system, internal medicine, analgesics, anti-infective, and consumer healthcare. It also offers medicines for the treatment of bone and joint diseases, and gastrointestinal disorders, as well as provides active pharmaceutical ingredients and intermediate products. In addition, the company is involved in the marketing and distribution of branded nutraceutical formulations. It also exports its products to Russia, Ukraine, Australia, the United Kingdom, Germany, and Sri Lanka. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. Sanofi India Limited was incorporated in 1956 and is based in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

3,291 Employees
Last Reported Date: 03/31/14
Founded in 1956

sanofi india ltd (SANL) Top Compensated Officers

Managing Director, Vice President of South As...
Total Annual Compensation: 8.6M
Chief Financial Officer, Chief Financial Offi...
Total Annual Compensation: 6.1M
Senior Director of Industrial Affairs for Sou...
Total Annual Compensation: 9.8M
Compensation as of Fiscal Year 2013.

sanofi india ltd (SANL) Key Developments

Sanofi India Limited Appoints N. Rajaram as Country Head and General Manager- Pharmaceutical Operations, India

Sanofi India Limited appointed N. Rajaram as Country Head and General Manager- Pharmaceutical Operations, India with effect from April 2014. He reports to Dr. Shailesh Ayyangar, Vice President - South Asia, Sanofi and Managing Director. He will be responsible for driving the company's ambitious growth plans in the Pharmaceutical and Consumer Healthcare segments.

Sanofi India Limited Recommends Final Dividend

Sanofi India Limited announced that the Board of Directors of the company at its meeting held on February 25, 2014 has recommended final dividend of INR 35 per equity shares of INR 10 for the year ended December 31, 2013.

Sanofi India Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Sanofi India Limited reported audited standalone earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net sales (net of excise duty) of INR 4,611 million against INR 4,007 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 900 million compared to INR 505 million last year. Profit before tax and exceptional items were INR 1,018 million compared to INR 663 million last year. Net profit before exceptional items was INR 673 million or INR 29.25 per basic and diluted share compared to INR 448 million or INR 19.49 per basic and diluted share last year. Net profit after exceptional items was INR 927 million or INR 40.29 per basic and diluted share compared to INR 448 million or INR 19.49 per basic and diluted share last year. For the year, the company reported net sales (net of excise duty) of INR 17,065 million against INR 14,939 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 3,056 million compared to INR 2,219 million last year. Profit before tax and exceptional items were INR 3,631 million compared to INR 2,617 million last year. Net profit before exceptional items was INR 2,398 million or INR 104.12 per basic and diluted share compared to INR 1,767 million or INR 76.71 per basic and diluted share last year. Net profit after exceptional items was INR 2,652 million or INR 115.14 per basic and diluted share compared to INR 1,767 million or INR 76.71 per basic and diluted share last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANL:IN 3,088.00 INR 0.00

SANL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 1,759 INR 0.00
Cadila Healthcare Ltd 974.75 INR 0.00
Medivation Inc $58.85 USD -1.19
Pfizer Ltd/India 1,308 INR 0.00
Piramal Enterprises Ltd 584.15 INR 0.00
View Industry Companies
 

Industry Analysis

SANL

Industry Average

Valuation SANL Industry Range
Price/Earnings 30.1x
Price/Sales 4.0x
Price/Book 5.4x
Price/Cash Flow 20.2x
TEV/Sales 3.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI INDIA LTD, please visit www.aventispharmaindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.